Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Schönborn – page 12

1 165 clinical trials in Bad Schönborn, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Schönborn at a glance
1 165
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 165 trials in Bad Schönborn

Open in trial search

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm

Recruiting

Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

FWY003 in Geographic Atrophy Secondary to Age-Related Macular Degeneration in Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:FWY003 tosilate
  • Sponsor:Novartis Pharma AG

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IKT-001PRO
  • Sponsor:Inhibikase Therapeutics Inc.

A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

A study to evaluate the effect of survodutide on protein levels in the urine for patients with chronic kidney disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Universitair Medisch Centrum Groningen

A study of PF-08634404, ipilimumab, and axitinib in adults with advanced or metastatic kidney cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Schönborn

What the registry says about research in the country

01 Chronic Sinusitis Research

Innovative clinical trials exploring LYR-210 depot therapy for patients with chronic rhinosinusitis who haven't responded to conventional treatments. This research focuses on improving the three cardinal symptoms of CRS in patients without nasal polyps.

  • Chronic Rhinosinusitis Management
  • Non-Polyp CRS Treatment
  • Alternative Therapeutic Approaches

Research aims to provide new options for patients who have exhausted traditional medical management strategies.

02 House Dust Mite Allergy Studies

Comprehensive evaluation of subcutaneous immunotherapy for moderate to severe allergic rhinitis and rhinoconjunctivitis. The research examines a specialized treatment protocol using PURETHAL Mites Mixture for patients with or without concurrent asthma.

  • Allergic Rhinitis Treatment
  • Immunotherapy Efficacy
  • Combined Symptom Management

This study measures treatment effectiveness through the Total Combined Rhinitis Score over a one-year period.

03 Seasonal Allergy Research

Investigation of PQ Birch therapy for seasonal allergic conditions, specifically targeting birch pollen-induced rhinitis and rhinoconjunctivitis. The research evaluates both safety and efficacy parameters.

  • Seasonal Rhinitis Treatment
  • Birch Pollen Allergies
  • Therapeutic Innovation

The study focuses on developing targeted solutions for seasonal allergy sufferers during birch pollen season.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.